The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Open accessAbstract
The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase–producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of AmpC-E, CRAB, and S. maltophilia infections. Answers are presented as suggested approaches and corresponding rationales. In contrast to guidance in the previous document, published data on the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited. As such, guidance in this document is provided as “suggested approaches” based on clinical experience, expert opinion, and a review of the available literature. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Preferred and alternative treatment suggestions are provided, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Suggestions apply for both adult and pediatric populations. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 17 September 2021 and will be updated annually. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance-2.0/.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during Therapy
Chow, J. W., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P., Ramphal, R., Wagener, M. M., Miyashiro, D. K., & Yu, V. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-8-585 · Cited by 889
Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Plasmid-Determined AmpC-Type β-Lactamases
Philippon, A., Arlet, G., & Jacoby, G. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.1-11.2002 · Cited by 816
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806
Association of adverse events with antibiotic use in hospitalized patients.
Tamma, P. D., Avdic, E., Li, D. X., Dzintars, K., & Cosgrove, S. E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1938 · Cited by 800
Self-citationThe role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii
Turton, J. F., Ward, M. E., Woodford, N., Kaufmann, M. E., Pike, R., Livermore, D. M., & Pitt, T. L. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00195.x · Cited by 751
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Self-citationPaul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y. D., Skiada, A., Andini, R., Eliakim-Raz, N., Nutman, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30099-9 · Cited by 623
Stenotrophomonas maltophilia: an emerging opportunist human pathogen
Looney, W. J., Narita, M., & Mühlemann, K. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70083-0 · Cited by 550
Interplay between β-lactamases and new β-lactamase inhibitors
Bush, K., & Bradford, P. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0159-8 · Cited by 531
New β-Lactam–β-Lactamase Inhibitor Combinations
Yahav, D., Giske, C. G., Grāmatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-20 · Cited by 521
Wunderink, R. G., Matsunaga, Y., Ariyasu, M., Clevenbergh, P., Echols, R., Kaye, K. S., Kollef, M., Menon, A., Pogue, J. M., Shorr, A. F., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30731-3 · Cited by 475
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Self-citationSandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Motsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Chang, Y.-T., Lin, C.-Y., Chen, Y.-H., & Hsueh, P.-R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00893 · Cited by 419
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 415
Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., Bassetti, M., Malacarne, P., Petrosillo, N., Galdieri, N., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit253 · Cited by 405
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Rifampin: Mechanisms of Action and Resistance
Wehrli, W. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s407 · Cited by 397
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Qureshi, Z. A., Hittle, L. E., O'Hara, J. A., Rivera, J. I., Syed, A., Shields, R. K., Pasculle, A. W., Ernst, R. K., & Doi, Y. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ048 · Cited by 395
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Pogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World
Tamma, P. D., Doi, Y., Bonomo, R. A., Johnson, J. K., Simner, P. J., Antibacterial Resistance Leadership Group, Tamma, P. D., Doi, Y., & Bonomo, R. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz173 · Cited by 322
Self-citationFalagas, M. E., Rafailidis, P. I., Ioannidou, E., Alexiou, V. G., Matthaiou, D. K., Karageorgopoulos, D. E., Kapaskelis, A., Nikita, D., & Michalopoulos, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.005 · Cited by 300
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Self-citationComparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Freire, A. T., Melnyk, V., Kim, M. J., Datsenko, O., Dzyublik, O., Glumcher, F., Chuang, Y.-C., Maroko, R. T., Dukart, G., Cooper, C. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.05.012 · Cited by 284
Kadri, S. S., Lai, Y. L., Warner, S., Strich, J. R., Babiker, A., Ricotta, E. E., Demirkale, C. Y., Dekker, J. P., Palmore, T. N., Rhee, C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30477-1 · Cited by 279
Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.4237 · Cited by 276
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Penwell, W. F., Shapiro, A. B., Giacobbe, R. A., Gu, R.-F., Gao, N., Thresher, J., McLaughlin, R. E., Huband, M. D., DeJonge, B. L. M., Ehmann, D. E., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04808-14 · Cited by 251
Satlin, M. J., Lewis, J. S., Weinstein, M. P., Patel, J., Humphries, R. M., Kahlmeter, G., Giske, C. G., & Turnidge, J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa121 · Cited by 250
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014) · Critical Care · doi:10.1186/cc13858 · Cited by 245
Sirijatuphat, R., & Thamlikitkul, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02435-13 · Cited by 235
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 235
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Stergiopoulou, T., Carmeli, Y., & Paul, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-13 · Cited by 233
Betrosian, A. P., Frantzeskaki, F., Xanthaki, A., & Douzinas, E. E. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.04.002 · Cited by 230
Nemec, A. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45716-0 · Cited by 226
AYDEMIR, H., AKDUMAN, D., PISKIN, N., COMERT, F., HORUZ, E., TERZI, A., KOKTURK, F., ORNEK, T., & CELEBI, G. (2013) · Epidemiology and Infection · doi:10.1017/s095026881200194x · Cited by 225
Rojas, L. J., Salim, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Marshall, S., Rudin, S. D., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw805 · Cited by 224
Self-citationMuder, R. R., Harris, A. P., Muller, S., Edmond, M., Chow, J. W., Papadakis, K., Wagener, M. W., Bodey, G. P., & Steckelberg, J. M. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.3.508 · Cited by 223
Safdar, A., & Rolston, K. V. (2007) · Clinical Infectious Diseases · doi:10.1086/522998 · Cited by 223
Solomkin, J. S., Gardovskis, J., Lawrence, K., Montravers, P., Sway, A., Evans, D., & Tsai, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1029 · Cited by 222
Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., Kosiek, K., Martinez de Tejada, B., Roux, X., Shiber, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.3627 · Cited by 214
Boisson, M., Jacobs, M., Grégoire, N., Gobin, P., Marchand, S., Couet, W., & Mimoz, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03510-14 · Cited by 211
Rattanaumpawan, P., Lorsutthitham, J., Ungprasert, P., Angkasekwinai, N., & Thamlikitkul, V. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq360 · Cited by 211
Michalopoulos, A., Kasiakou, S. K., Mastora, Z., Rellos, K., Kapaskelis, A. M., & Falagas, M. E. (2004) · Critical Care · doi:10.1186/cc3020 · Cited by 209
Marchaim, D., Chopra, T., Pogue, J. M., Perez, F., Hujer, A. M., Rudin, S., Endimiani, A., Navon-Venezia, S., Hothi, J., Slim, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-10 · Cited by 208
Self-citationLu, Q., Luo, R., Bodin, L., Yang, J., Zahr, N., Aubry, A., Golmard, J.-L., & Rouby, J.-J. (2012) · Anesthesiology · doi:10.1097/aln.0b013e31827515de · Cited by 207
Kofteridis, D. P., Alexopoulou, C., Valachis, A., Maraki, S., Dimopoulou, D., Georgopoulos, D., & Samonis, G. (2010) · Clinical Infectious Diseases · doi:10.1086/657242 · Cited by 207
Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene
Ito, R., Mustapha, M. M., Tomich, A. D., Callaghan, J. D., McElheny, C. L., Mettus, R. T., Shanks, R. M. Q., Sluis-Cremer, N., & Doi, Y. (2017) · mBio · doi:10.1128/mbio.00749-17 · Cited by 204
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-17 · Cited by 202
Ito, A., Kohira, N., Bouchillon, S. K., West, J., Rittenhouse, S., Sader, H. S., Rhomberg, P. R., Jones, R. N., Yoshizawa, H., Nakamura, R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv402 · Cited by 192
Michalopoulos, A., Fotakis, D., Virtzili, S., Vletsas, C., Raftopoulou, S., Mastora, Z., & Falagas, M. E. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.10.011 · Cited by 191
Kwa, A. L. H., Loh, C., Low, J. G. H., Kurup, A., & Tam, V. H. (2005) · Clinical Infectious Diseases · doi:10.1086/432583 · Cited by 191
Yamano, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz827 · Cited by 191
Choi, S.-H., Lee, J. E., Park, S. J., Choi, S.-H., Lee, S.-O., Jeong, J.-Y., Kim, M.-N., Woo, J. H., & Kim, Y. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-07 · Cited by 190
Zhang, L., Li, X.-Z., & Poole, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.287-293.2000 · Cited by 190
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Tamma, P. D., & Rodriguez-Baňo, J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix034 · Cited by 186
Self-citationRegulatory components in Citrobacter freundii ampC beta-lactamase induction.
Lindberg, F., Westman, L., & Normark, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.14.4620 · Cited by 182
Batirel, A., Balkan, I. I., Karabay, O., Agalar, C., Akalin, S., Alici, O., Alp, E., Altay, F. A., Altin, N., Arslan, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2070-6 · Cited by 182
Tumbarello, M., De Pascale, G., Trecarichi, E. M., De Martino, S., Bello, G., Maviglia, R., Spanu, T., & Antonelli, M. (2013) · Chest · doi:10.1378/chest.13-1018 · Cited by 182
Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter spp
Kaye, K. S., Cosgrove, S., Harris, A., Eliopoulos, G. M., & Carmeli, Y. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2628-2630.2001 · Cited by 181
Falagas, M. E., Valkimadi, P.-E., Huang, Y.-T., Matthaiou, D. K., & Hsueh, P.-R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn301 · Cited by 181
Honoré, N., Nicolas, M. H., & Cole, S. T. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04704.x · Cited by 180
Falagas, M. E., Kastoris, A. C., Vouloumanou, E. K., Rafailidis, P. I., Kapaskelis, A. M., & Dimopoulos, G. (2009) · Future Microbiology · doi:10.2217/fmb.09.84 · Cited by 179
Bacteremia Due to Stenotrophomonas maltophilia in Patients with Hematologic Malignancies
Micozzi, A., Venditti, M., Monaco, M., Friedrich, A., Taglietti, F., Santilli, S., & Martino, P. (2000) · Clinical Infectious Diseases · doi:10.1086/314043 · Cited by 176
Kollef, M. H., Ricard, J.-D., Roux, D., Francois, B., Ischaki, E., Rozgonyi, Z., Boulain, T., Ivanyi, Z., János, G., Garot, D., et al. (2017) · Chest · doi:10.1016/j.chest.2016.11.026 · Cited by 173
The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae
Tamma, P. D., Girdwood, S. C. T., Gopaul, R., Tekle, T., Roberts, A. A., Harris, A. D., Cosgrove, S. E., & Carroll, K. C. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit395 · Cited by 172
Self-citationLesho, E., Yoon, E.-J., McGann, P., Snesrud, E., Kwak, Y., Milillo, M., Onmus-Leone, F., Preston, L., St. Clair, K., Nikolich, M., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit293 · Cited by 171
Korbila, I. P., Michalopoulos, A., Rafailidis, P. I., Nikita, D., Samonis, G., & Falagas, M. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03040.x · Cited by 170
Rello, J., Solé-Lleonart, C., Rouby, J.-J., Chastre, J., Blot, S., Poulakou, G., Luyt, C.-E., Riera, J., Palmer, L. B., Pereira, J. M., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.04.011 · Cited by 167
Jacobson, K. L., Cohen, S. H., Inciardi, J. F., King, J. H., Lippert, W. E., Iglesias, T., & VanCouwenberghe, C. J. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1107 · Cited by 165
Motaouakkil, S., Charra, B., Hachimi, A., Nejmi, H., Benslama, A., Elmdaghri, N., Belabbes, H., & Benbachir, M. (2006) · Journal of Infection · doi:10.1016/j.jinf.2005.11.019 · Cited by 165
New Perspectives on Antimicrobial Agents: Cefiderocol
McCreary, E. K., Heil, E. L., & Tamma, P. D. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02171-20 · Cited by 165
Self-citationTamma, P. D., Conley, A. T., Cosgrove, S. E., Harris, A. D., Lautenbach, E., Amoah, J., Avdic, E., Tolomeo, P., Wise, J., Subudhi, S., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.6226 · Cited by 160
Self-citationGröschel, M. I., Meehan, C. J., Barilar, I., Diricks, M., Gonzaga, A., Steglich, M., Conchillo‐Solé, O., Scherer, I.-C., Mamat, U., Luz, C. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15123-0 · Cited by 157
Liu, J., Shu, Y., Zhu, F., Feng, B., Zhang, Z., Liu, L., & Wang, G. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.08.021 · Cited by 157
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Berlana, D., Llop, J. M., Casamartina, E. F., Badia, M., & Jódar, R. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.1.39 · Cited by 155
Livermore, D. M., Mushtaq, S., Warner, M., & Woodford, N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00436-16 · Cited by 152
Inhaled Antibiotics for Gram-Negative Respiratory Infections
Wenzler, E., Fraidenburg, D. R., Scardina, T. L., & Danziger, L. H. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-15 · Cited by 151
Dobias, J., Tendon, V. D., Poirel, L., & Nordmann, P. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3063-z · Cited by 151
Karlowsky, J. A., Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Sahm, D. F. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.007 · Cited by 149
Montero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., Tubau, F., Borraz, C., & Gudiol, F. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh485 · Cited by 148
Abdellatif, S., Trifi, A., Daly, F., Mahjoub, K., Nasri, R., & Lakhal, S. B. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0127-7 · Cited by 148
Páez, J. I. G., & Costa, S. F. (2008) · Journal of Hospital Infection · doi:10.1016/j.jhin.2008.05.020 · Cited by 146
Rifamycins, Alone and in CombinationPreprint
Rothstein, D. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027011 · Cited by 145
Shields, R. K., Clancy, C. J., Gillis, L. M., Kwak, E. J., Silveira, F. P., Abdel-Massih, R. C., Eschenauer, G. A., Potoski, B. A., & Nguyen, M. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052349 · Cited by 144
Self-citationAbdallah, M., Olafisoye, O., Cortes, C. D., Urban, C. M., Landman, D., & Quale, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04809-14 · Cited by 144
Montero, A., Ariza, J., Corbella, X., Domenech, A., Cabellos, C., Ayats, J., Tubau, F., Ardanuy, C., & Gudiol, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1946-1952.2002 · Cited by 143
Landersdorfer, C. B., Wang, J., Wirth, V., Chen, K., Kaye, K. S., Tsuji, B. T., Li, J., & Nation, R. L. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx409 · Cited by 143
Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
Nation, R. L., Rigatto, M. H., Falci, D. R., & Zavascki, A. P. (2019) · Antibiotics · doi:10.3390/antibiotics8010024 · Cited by 140
Emeraud, C., Escaut, L., Boucly, A., Fortineau, N., Bonnin, R. A., Naas, T., & Dortet, L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00010-19 · Cited by 136
Niederman, M. S., Alder, J. D., Bassetti, M., Boateng, F., Cao, B., Corkery, K. J., Dhand, R., Kaye, K. S., Lawatscheck, R., McLeroth, P., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30574-2 · Cited by 132
Betrosian, A. P., Frantzeskaki, F. G., Xanthaki, A., & Georgiadis, G. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600951184 · Cited by 131
Wang, Y. L., Scipione, M. R., Dubrovskaya, Y., & Papadopoulos, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-13 · Cited by 130
Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations
Papp‐Wallace, K. M., Mack, A. R., Taracila, M. A., & Bonomo, R. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.001 · Cited by 130
Self-citationJung, S. Y., Lee, S. H., Lee, S., Yang, S., Noh, H., Chung, E. K., & Lee, J. I. (2017) · Critical Care · doi:10.1186/s13054-017-1916-6 · Cited by 129
Zha, L., Pan, L., Guo, J., French, N., Villanueva, E., & Tefsen, B. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01235-y · Cited by 129
Barnhill, A. E., Brewer, M. T., & Carlson, S. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00678-12 · Cited by 126
Karlowsky, J. A., Biedenbach, D. J., Kazmierczak, K. M., Stone, G. G., & Sahm, D. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-15 · Cited by 126
Chuang, Y., Cheng, C., Sheng, W., Sun, H., Wang, J., Chen, Y., & Chang, S. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-102 · Cited by 125
Dickstein, Y., Lellouche, J., Dalak, M. A. B., Schwartz, D. A., Nutman, A., Daitch, V., Yahav, D., Leibovici, L., Skiada, A., Antoniadou, A., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy988 · Cited by 125
Grillon, A., Schramm, F., Kleinberg, M., & Jehl, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156690 · Cited by 124
Charrel, R. N., Pagès, J., de Micco, P., & Malléa, M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2854 · Cited by 123
Presence of Tetracycline Resistance Determinants and Susceptibility to Tigecycline and Minocycline
Fluit, A. C., Florijn, A., Verhoef, J., & Milatović, D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1636-1638.2005 · Cited by 122
Kohlmann, R., Bähr, T., & Gatermann, S. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky084 · Cited by 120
Papp‐Wallace, K. M., Bethel, C. R., Caillon, J., Barnes, M. D., Potel, G., Bajaksouzian, S., Rutter, J. D., Reghal, A., Shapiro, S., Taracila, M. A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-19 · Cited by 120
Self-citationFreire, M. P., Garcia, D. D. O., Garcia, C. P., Bueno, M. F. C., Camargo, C. H., Magri, A. S. G. K., Francisco, G. R., da Silva, R. R., Vieira, M. F., Ibrahim, K. Y., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.010 · Cited by 119
Nakamura, R., Ito-Horiyama, T., Takemura, M., Toba, S., Matsumoto, S., Ikehara, T., Tsuji, M., Sato, T., & Yamano, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-18 · Cited by 119
Accurate Identification of Clinically Important Acinetobacter Spp.: An Update
Vijayakumar, S., Biswas, I., & Veeraraghavan, B. (2019) · Future Science OA · doi:10.2144/fsoa-2018-0127 · Cited by 119
Ko, J., Kang, C., Cornejo‐Juárez, P., Yeh, K., Wang, C.-H., Cho, S. Y., Gözel, M. G., Kim, S., Hsueh, P., Sekiya, N., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.008 · Cited by 118
Goodlet, K. J., Benhalima, F. Z., & Nailor, M. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02165-18 · Cited by 116
Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors
Trifonova, A., & Strateva, T. (2018) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2018.1531145 · Cited by 116
Farrell, D. J., Sader, H. S., & Jones, R. N. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01774-09 · Cited by 111
Kuo, L.-C., Lai, C., Liao, C., Hsu, C.-K., Chang, Y.-L., Chang, C.-Y., & Hsueh, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01601.x · Cited by 110
Molecular basis of beta-lactamase induction in bacteria
Bennett, P. M., & Chopra, I. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.153 · Cited by 109
Synergistic combinations of polymyxins
Lenhard, J. R., Nation, R. L., & Tsuji, B. T. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.014 · Cited by 108
Seifert, H., Stefanik, D., Sutcliffe, J. A., & Higgins, P. G. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.022 · Cited by 108
Hsueh, S.-C., Lee, Y., Huang, Y., Liao, C., Tsuji, M., & Hsueh, P. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky425 · Cited by 108
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
Maselli, D. J., Keyt, H., & Restrepo, M. I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051062 · Cited by 107
Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens
Poulakou, G., Kontopidou, F. V., Paramythiotou, E., Kompoti, M., Katsiari, M., Mainas, E., Nicolaou, C., Yphantis, D., Antoniadou, A., Trikka‐Graphakos, E., et al. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.02.009 · Cited by 106
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint
Burkhardt, O., Rauch, K., Kaever, V., Hadem, J., Kielstein, J. T., & Welte, T. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.015 · Cited by 106
Hancock, R. E. W., & Bellido, F. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.suppl_a.1 · Cited by 105
Cho, S. Y., Kang, C., Kim, J., Ha, Y. E., Chung, D. R., Lee, N. Y., Peck, K. R., & Song, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01682-13 · Cited by 105
Petrosillo, N., Giannella, M., Antonelli, M. M., Antonini, M., Baršić, B., Belancic, L., İnkaya, A. Ç., PASCALE, G. D., Grilli, E., Tumbarello, M., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-13 · Cited by 103
Kalın, G., Alp, E., Demiraslan, H., Doğanay, M., Coskun, R., & Gündoğan, K. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0430-7 · Cited by 101
Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with Potent β-Lactamases
Livermore, D. M., Oakton, K. J., Carter, M. W., & Warner, M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2831-2837.2001 · Cited by 101
Monogue, M. L., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Nicolau, D. P. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01022-17 · Cited by 101
López-Cortés, L. F., Cisneros, J. M., Fernández-Cuenca, F., Bou, G., Tomás, M., Garnacho‐Montero, J., Pascual, Á., Martı́nez-Martı́nez, L., Vilà, J., Pachón, J., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku233 · Cited by 100
Heil, E. L., Bork, J. T., Abbo, L. M., Barlam, T. F., Cosgrove, S. E., Davis, A. E., Ha, D. R., Jenkins, T. C., Kaye, K. S., Lewis, J. S., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab434 · Cited by 100
Self-citationMojica, M. F., Rutter, J. D., Taracila, M. A., Abriata, L. A., Fouts, D. E., Papp‐Wallace, K. M., Walsh, T. J., LiPuma, J. J., Vila, A. J., & Bonomo, R. A. (2019) · mBio · doi:10.1128/mbio.00405-19 · Cited by 99
Self-citationShields, R. K., Iovleva, A., Kline, E. G., Kawai, A., McElheny, C. L., & Doi, Y. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa355 · Cited by 99
Cheng, L., Nelson, B. C., Mehta, M., Seval, N., Park, S. E., Giddins, M. J., Shi, Q., Whittier, S., Gomez‐Simmonds, A., & Uhlemann, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-17 · Cited by 98
Makris, D. A., Petinaki, E., Tsolaki, V., Manoulakas, E., Mantzarlis, K. D., Apostolopoulou, O., Sfyras, D., & Zakynthinos, E. G. (2018) · Indian Journal of Critical Care Medicine · doi:10.4103/ijccm.ijccm_302_17 · Cited by 98
Stewart, A. G., Paterson, D. L., Young, B. E., Lye, D. C., Davis, J. S., Schneider, K., Yılmaz, M., Dinleyici, R., Runnegar, N. J., Henderson, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab387 · Cited by 98
Falagas, M. E., Vardakas, K. Z., Tsiveriotis, K., Triarides, N. A., & Tansarli, G. S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.006 · Cited by 97
Kalın, G., Alp, E., Akin, A., Coskun, R., & Doğanay, M. (2013) · Infection · doi:10.1007/s15010-013-0495-y · Cited by 97
Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
Siedner, M. J., Galar, A., Guzmán‐Suarez, B. B., Kubiak, D. W., Baghdady, N., Ferraro, M. J., Hooper, D. C., O’Brien, T. F., & Marty, F. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu182 · Cited by 97
Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.
Al-Jasser, A. M. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-23 · Cited by 96
Falagas, M. E., Kasiakou, S. K., Kofteridis, D. P., Roditakis, G., & Samonis, G. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0191-2 · Cited by 95
Aerosolized Antibiotics for Ventilator-associated Pneumonia
Rouby, J., Bouhemad, B., Monsel, A., Brisson, H., Arbelot, C., & Lü, Q. (2012) · Anesthesiology · doi:10.1097/aln.0b013e3182755d7a · Cited by 95
Wood, G. C., Hanes, S. D., Boucher, B. A., Croce, M. A., & Fabian, T. C. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1811-2 · Cited by 93
Krizova, L., Poirel, L., Nordmann, P., & Nemec, A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt275 · Cited by 93
A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
Ritchie, D. J., & Garavaglia-Wilson, A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu613 · Cited by 92
Aph(3′)-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia
Okazaki, A., & Avison, M. B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00795-06 · Cited by 92
Harris, P. N. A., Wei, J. Y., Shen, A., Abdile, A. A., Paynter, S., Huxley, R., Pandeya, N., Doi, Y., Huh, K., O’Neal, C. S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv346 · Cited by 92
Araoka, H., Baba, M., & Yoneyama, A. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-0882-6 · Cited by 90
Zelenitsky, S. A., Iacovides, H., Ariano, R. E., & Harding, G. K. M. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.09.002 · Cited by 89
López-Rojas, R., McConnell, M. J., Me, J.-M., Domínguez-Herrera, J., Fernández-Cuenca, F., & Pachón, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-13 · Cited by 88
Castanheira, M., Mendes, R. E., & Jones, R. N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu706 · Cited by 88
Kim, W., Moon, J.-Y., Huh, J. W., Choi, S., Lim, C., Koh, Y., Chong, Y. P., & Hong, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150642 · Cited by 88
Lenhard, J. R., Smith, N. M., Bulman, Z. P., Tao, X., Thamlikitkul, V., Shin, B. S., Nation, R. L., Li, J., Bulitta, J. B., & Tsuji, B. T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01268-16 · Cited by 88
Liang, C.-A., Lin, Y.-C., Lu, P., Chen, H.-C., Chang, H.-M., & Sheu, C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.10.033 · Cited by 87
Kawai, A., McElheny, C. L., Iovleva, A., Kline, E. G., Sluis‐Cremer, N., Shields, R. K., & Doi, Y. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00198-20 · Cited by 87
Chan, J. D., Graves, J. A., & Dellit, T. H. (2010) · Journal of Intensive Care Medicine · doi:10.1177/0885066610377975 · Cited by 85
Wei, C., Ni, W., Cai, X., Zhao, J., & Cui, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152132 · Cited by 84
Butler, D. A., Biagi, M. J., Tan, X., Qasmieh, S., Bulman, Z. P., & Wenzler, E. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0706-5 · Cited by 84
Lee, N., Lee, C., Li, C., Li, M.-C., Chen, P., Chang, C., & Ko, W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01477-15 · Cited by 83
Punjabi, C. D., Tien, V., Meng, L., Deresinski, S. C., & Holubar, M. K. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz364 · Cited by 83
Lodise, T. P., Smith, N. M., O’Donnell, J. N., Eakin, A. E., Holden, P. N., Boissonneault, K. R., Zhou, J., Tao, X., Bulitta, J. B., Fowler, V. G., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa197 · Cited by 83
Self-citationReddy, T., Chopra, T., Marchaim, D., Pogue, J. M., Alangaden, G. J., Salimnia, H., Boikov, D. A., Navon‐Venezia, S., Akins, R. A., Selman, P., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01665-09 · Cited by 81
Mojica, M. F., Papp‐Wallace, K. M., Taracila, M. A., Barnes, M. D., Rutter, J. D., Jacobs, M. R., LiPuma, J. J., Walsh, T. J., Vila, A. J., & Bonomo, R. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00777-17 · Cited by 81
Self-citationKawaguchi, N., Katsube, T., ECHOLS, R. M., & Wajima, T. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01437-20 · Cited by 81
ALLEN, J. C. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-85-4-482 · Cited by 80
Mojica, M. F., Ouellette, C. P., Leber, A. L., Becknell, B., Ardura, M. I., Pérez, F., Shimamura, M., Bonomo, R. A., Aitken, S. L., & Shelburne, S. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00264-16 · Cited by 80
Self-citationDiverse potential of beta-lactamase inhibitors to induce class I enzymes
Weber, D. A., & Sanders, C. C. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.156 · Cited by 77
Hand, E., Davis, H., Kim, T., & Duhon, B. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv456 · Cited by 77
Cotrimoxazole - optimal dosing in the critically ill
Brown, G. R. (2014) · Annals of Intensive Care · doi:10.1186/2110-5820-4-13 · Cited by 76
Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumannii
Bowers, D. R., Cao, H., Zhou, J. M., Ledesma, K. R., Sun, D., Lomovskaya, O., & Tam, V. H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04110-14 · Cited by 76
Forrest, A., Merali, S. J., Thamlikitkul, V., Giamarellos‐Bourboulis, E. J., Paterson, D. L., Li, J., Silveira, F. P., & Nation, R. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01367-17 · Cited by 76
Doshi, N., Cook, C. H., Mount, K. L., Stawicki, S. P., Frazee, E. N., Personett, H. A., Schramm, G. E., Arnold, H. M., & Murphy, C. V. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-45 · Cited by 75
Castanheira, M., Deshpande, L. M., Woosley, L. N., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky344 · Cited by 75
Cho, S., Lee, D., Choi, S., Park, C., Chun, H., Park, Y.-J., Choi, J.-K., Lee, H.-J., Park, S. H., Choi, J., et al. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0801-7 · Cited by 74
Demırdal, T., Sarı, Ü. S., & Nemli, S. A. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0123-7 · Cited by 74
YILMAZ, G. R., Güven, T., Güner, R., Tufan, Z. K., İzdeş, Ş., Tasyaran, M. A., & Açıkgöz, Z. C. (2015) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.6195 · Cited by 72
Park, H. J., Cho, J. H., Kim, H. J., Han, S. H., Jeong, S. H., & Byun, M. K. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.11.016 · Cited by 72
Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia
Jeon, Y. D., Jeong, W., Kim, M. H., Jung, I. Y., Ahn, M. Y., Ann, H. W., Ahn, J. Y., Han, S. H., Choi, J. Y., Song, Y. G., et al. (2016) · Medicine · doi:10.1097/md.0000000000004375 · Cited by 71
Pfaller, M. A., Huband, M. D., Shortridge, D., & Flamm, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02327-17 · Cited by 71
Luna, B. M., Trebosc, V., Lee, B., Bakowski, M. A., Ulhaq, A., Yan, J., Lu, P., Cheng, J., Nielsen, T. B., Lim, J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0737-6 · Cited by 71
Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
PASCALE, G. D., Lisi, L., Ciotti, G. M. P., Vallecoccia, M. S., Cutuli, S. L., Cascarano, L., Gelormini, C., Bello, G., Montini, L. M., Carelli, S., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00715-2 · Cited by 71
Rodríguez-Hernández, M. J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.479 · Cited by 70
Horcajada, J. P., Sorlí, L., Luque, S., Benito, N., Segura, C., Campillo, N., Montero, M., Esteve, E., Mirelis, B., Pomar, V., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.08.020 · Cited by 70
McLeod, S. M., Shapiro, A. B., Moussa, S. H., Johnstone, M. R., McLaughlin, R. E., DeJonge, B. L. M., & Miller, A. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01576-17 · Cited by 69
Risk factors for death from Stenotrophomonas maltophilia bacteremia
Osawa, K., Shigemura, K., Kitagawa, K., Tokimatsu, I., & Fujisawa, M. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.03.011 · Cited by 68
Petrella, S., Clermont, D., Casin, I., Jarlier, V., & Sougakoff, W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.8.2287-2298.2001 · Cited by 66
Hilty, M., Sendi, P., Seiffert, S. N., Droz, S., Perreten, V., Hujer, A. M., Bonomo, R. A., Mühlemann, K., & Endimiani, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.022 · Cited by 65
Self-citationMoskowitz, S. M., Garber, E., Chen, Y., Clock, S. A., Tabibi, S., Miller, A. K., Doctor, M., & Saiman, L. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq131 · Cited by 65
Biagi, M. J., Tan, X., Wu, T.-S., Jurkovic, M., Vialichka, A., Meyer, K., Mendes, R. E., & Wenzler, E. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01603-19 · Cited by 65
Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii
Tseng, Y., Wang, J., Wu, F. L., Chen, Y., Chie, W., & Chang, S. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.04.024 · Cited by 64
Goff, D. A., Bauer, K. A. A., & Mangino, J. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu593 · Cited by 64
Biagi, M. J., Vialichka, A., Jurkovic, M., Wu, T.-S., Shajee, A., Lee, M., Patel, S., Mendes, R. E., & Wenzler, E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-20 · Cited by 64
Naesens, R., Vlieghe, E., Verbrugghe, W., Jorens, P. G., & Ieven, M. M. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-317 · Cited by 63
Risk factors for nephrotoxicity onset associated with polymyxin B therapy
Dubrovskaya, Y., Prasad, N., Lee, Y., Esaian, D., Figueroa, D. A., & Tam, V. H. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv014 · Cited by 63
Cited by
A novel antibiotic class targeting the lipopolysaccharide transporter
Zampaloni, C., Mattei, P., Bleicher, K., Winther, L., Thäte, C., Bucher, C., Adam, J.-M., Alanine, A., Amrein, K. E., Baidin, V., et al. (2024) · Nature · doi:10.1038/s41586-023-06873-0 · Cited by 308
Treatment of Acinetobacter baumannii severe infections
Reina, R., León-Moya, C., & Garnacho-Montero, J. (2022) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2022.08.007 · Cited by 22
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-12-05
- Volume
- 74
- Issue
- 12
- Pages
- 2089-2114
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4200036649
- Cited by
- 519
- References
- 318
- FWCI
- 25.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.